- Home
- LMRI vs MESO Comparison
LMRI vs MESO Comparison
Compare LMRI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LMRI | MESO |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | LMRI | MESO |
|---|---|---|
| Price | $18.63 | $17.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 3.9M | 211.8K |
| Earning Date | 01-01-0001 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,375,000.00 | $17,198,000.00 |
| Revenue This Year | N/A | $465.44 |
| Revenue Next Year | N/A | $75.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $18.03 | $9.61 |
| 52 Week High | $19.25 | $22.00 |
Technical Indicators
Market Signals| Indicator | LMRI | MESO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.73 |
| Support Level | N/A | $16.43 |
| Resistance Level | N/A | $17.65 |
| Average True Range (ATR) | 0.00 | 0.59 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 0.00 | 56.31 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.